New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2013
16:00 EDTOPKOPKO citicoline products approved for commercialization in Spain
OPKO Health announced that its Barcelona, Spain subsidiary, Pharmadiet, S.L.U., received regulatory approval from Spainís health authority for commercialization of its oral and injectable formulations of citicoline. Final marketing authorization is expected within 60 to 90 days.
News For OPK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 28, 2015
08:29 EDTOPKOPKO Health long-term thesis intact despite selloff, says Barrington
Subscribe for More Information
September 20, 2015
13:59 EDTOPKOPKO Health may face challenge with Bio-Reference acquisition, Barron's says
OPKO Health (OPK) "could face a big challenge" with its acquisition of Bio-Reference, Barron's contends in its 'Follow Up' column. Barron's conducted recent interviews with former Bio-Reference salespeople, who allege that the company pushed expensive, unnecessary tests on patients, resulting in pushback from health insurers. Additionally, the former employees claim the company was willing to waive patient co-payments in order to better compete with LabCorp (LH) and Quest Diagnostics (DX), says Barron's. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use